A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma

Gaudio, Francesco; Loseto, Giacomo; Bozzoli, Valentina; Scalzulli, Potito Rosario; Mazzone, A.; Tonialini, Lorenzo; Fesce, V.; Quintana, Giovanni; Santis, Gaetano De; Masciopinto, Pierluigi; Arcuti, Elena; Clemente, Felice; Scardino, Stefania; Tarantini, Giuseppe; Pastore, Domenico; Melillo, Leone; Pavone, Vincenzo; Maggi, Alessandro; Carella, Angelo Michele; Renzo, Nicola Di; Guarini, Attilio; Musto, Pellegrino

doi:10.1007/s00277-023-05100-0

Cited by 3 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These late treatment sequelae can negatively affect survivor's health and predispose to premature death. 1,7,8,21,22 Death in the rst ten years after diagnosis is largely attributable to HL. With extended follow-up beyond ten years, treatment complications, predominantly secondary cancers and cardiovascular disease, emerge as leading causes of excess death and exhibit novel sex relationships in this young cohort.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Breast Parenchyma in Chest Radiotreated Survivors of Hodgkin's Lymphoma and Healthy Women with Brca Mutation Carriers: A Case Control Study

Laddaga,

Telegrafo,

Garzillo

et al. 2024

Preprint

View full text Add to dashboard Cite

Increased background parenchymal enhancement (BPE) is an imaging biomarker of higher risk of BC. The aim of this prospective study was to evaluate the distribution of BPE patterns and the possible onset of BC in long-term HL survivors treated with chemotherapy and RT and to compare them with age-matched women with BRCA mutation carriers and without a history of cancer. 62 women, long-term survivors of HL for at least 15 years and 62 consecutive women of the same age with BRCA mutation carriers, underwent screening with dynamic contrast magnetic resonance imaging. BPE was comparable in the two groups: 31 cases (50%) of moderate and marked BPE in the long-surviving HL group and 30 (48%) in the BRCA carrier control group. In the long-surviving HL group, 3 (5%) malignant lesions were found, two of these (ductal carcinoma in situ-DCIS, n = 1; non-special type-NST, n = 1) had moderate BPE lesions in the contralateral breast and one (NST ) marked BPE. We found a BPE comparable to healthy women at high risk for BC with BRCA mutation carriers. Future research should be directed at examining the underlying cancer biology and genetic susceptibility of treatment-induced tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Breast Parenchyma in Chest Radiotreated Survivors of Hodgkin's Lymphoma and Healthy Women with Brca Mutation Carriers: A Case Control Study

Laddaga,

Telegrafo,

Garzillo

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Sequencing novel agents in the treatment of classical Hodgkin lymphoma

Ferhanoglu,

Ozbalak

2023

Expert Review of Hematology

View full text Add to dashboard Cite

Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin’s lymphoma

Oyake,

Maeta,

Takahata

et al. 2024

JCEH

View full text Add to dashboard Cite

Hodgkin's lymphoma (HL) accounts for approximately 30% of all malignant lymphomas in Europe and the United States. 1 In Japan, HL accounts for approximately 5-10% of all malignant lymphoma cases. 2 Chemotherapy with ABVD (ADR: doxorubicin, BLM: bleomycin, VBL: vinblastine, DTIC: dacarbazine) or BV (brentuximab vedotin)-AVD (DXR, VBL, DTIC) has been the standard of care for the first-line treatment of classical HL, along with radiation ther-

show abstract

A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma

Cited by 3 publications

References 29 publications

Comparison of Breast Parenchyma in Chest Radiotreated Survivors of Hodgkin's Lymphoma and Healthy Women with Brca Mutation Carriers: A Case Control Study

Comparison of Breast Parenchyma in Chest Radiotreated Survivors of Hodgkin's Lymphoma and Healthy Women with Brca Mutation Carriers: A Case Control Study

Sequencing novel agents in the treatment of classical Hodgkin lymphoma

Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin’s lymphoma

Contact Info

Product

Resources

About